Targeting Pericyte Differentiation as a Strategy to Modulate Kidney Fibrosis in Diabetic Nephropathy

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 463-470

  Humphreys, Benjamin D ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; SONIC HEDGEHOG PROTEIN INHIBITOR; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL CARCINOMA; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRUCTURE; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; MEDULLOBLASTOMA; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FIBROSIS; HUMANS; KIDNEY; MYOFIBROBLASTS; PERICYTES;

EID: 84867382214     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.009     Document Type: Article

References (81)

1. Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968, 2:363-366.
2. Nath K.A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
3. Katz A., Caramori M.L., Sisson-Ross S., et al. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 2002, 61:2058-2066.
4. Fioretto P., Mauer M., Brocco E., et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996, 39:1569-1576.
5. Essawy M., Soylemezoglu O., Muchaneta-Kubara E.C., et al. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997, 12:43-50.
6. Basile D.P. Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens 2004, 13:1-7.
7. Fioretto P., Steffes M.W., Sutherland D.E., et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
8. Diaz-Flores L., Gutierrez R., Madrid J.F., et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 2009, 24:909-969.
9. Courtnoy P., Boyles J. Fibronectin in the microvasculature: localization in the pericyte-endothelial interstitium. J Ultrastruct Res 1983, 83:258-273.
10. Rouget C. Memoire sur le developpement, la structure et les proprietes physiologiques des capillaries sanguins et lymphatiques. Arch Physiol Norm Pathol 1873, 5:603-663.
11. Zimmerman K. Der feinere bau der blutcapillaren. Z Anat Entwicklungsgeschichte 1923, 68:29-36.
12. Takahashi-Iwanaga H. The three-dimensional cytoarchitecture of the interstitial tissue in the rat kidney. Cell Tissue Res 1991, 264:269-281.
13. Fujimoto K. Pericyte-endothelial gap junctions in developing rat cerebral capillaries: a fine structural study. Anat Rec 1995, 242:562-565.
14. Kaissling B., Hegyi I., Loffing J., et al. Morphology of interstitial cells in the healthy kidney. Anat Embryol (Berl) 1996, 193:303-318.
15. Kriz W., Kaissling B., Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J Clin Invest 2011, 121:468-474.
16. Asada N., Takase M., Nakamura J., et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011, 121:3981-3990.
17. Park F., Mattson D.L., Roberts L.A., et al. Evidence for the presence of smooth muscle alpha-actin within pericytes of the renal medulla. Am J Physiol 1997, 273:R1742-R1748.
18. Pallone T.L., Silldorff E.P. Pericyte regulation of renal medullary blood flow. Exp Nephrol 2001, 9:165-170.
19. Crisan M., Yap S., Casteilla L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
20. Goritz C., Dias D.O., Tomilin N., et al. A pericyte origin of spinal cord scar tissue. Science 2011, 333:238-242.
21. Nehls V., Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol 1991, 113:147-154.
22. Lin S.L., Kisseleva T., Brenner D.A., et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
23. Sundberg C., Ljungstrom M., Lindmark G., et al. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993, 143:1377-1388.
24. Eyden B. The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. Part 2-tumours and tumour-like lesions. J Submicrosc Cytol Pathol 2005, 37:231-296.
25. Gabbiani G. The cellular derivation and the life span of the myofibroblast. Pathol Res Pract 1996, 192:708-711.
26. Rajkumar V.S., Howell K., Csiszar K., et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005, 7:R1113-R1123.
27. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119:1429-1437.
28. Humphreys B.D., Lin S.L., Kobayashi A., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
29. Grgic I., Duffield J.S., Humphreys B.D. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012, 27:183-193.
30. Zeisberg E.M., Potenta S.E., Sugimoto H., et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008, 19:2282-2287.
31. Rock J.R., Barkauskas C.E., Cronce M.J., et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A 2011, 108:E1475-E1483.
32. Ingham P.W., McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001, 15:3059-3087.
33. Mao J., Kim B.M., Rajurkar M., et al. Hedgehog signaling controls mesenchymal growth in the developing mammalian digestive tract. Development 2010, 137:1721-1729.
34. Yu J., Carroll T.J., McMahon A.P. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development 2002, 129:5301-5312.
35. Cain J.E., Rosenblum N.D. Control of mammalian kidney development by the Hedgehog signaling pathway. Pediatr Nephrol 2011, 26:1365-1371.
36. Hu M.C., Mo R., Bhella S., et al. GLI3-dependent transcriptional repression of Gli1, Gli2 and kidney patterning genes disrupts renal morphogenesis. Development 2006, 133:569-578.
37. Sasaki H., Nishizaki Y., Hui C., et al. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999, 126:3915-3924.
38. Tian H., Callahan C.A., DuPree K.J., et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009, 106:4254-4259.
39. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
40. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
41. Shin K., Lee J., Guo N., et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 2011, 472:110-114.
42. Omenetti A., Porrello A., Jung Y., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008, 118:3331-3342.
43. Syn W.K., Choi S.S., Liaskou E., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53:106-115.
44. Choi S.S., Omenetti A., Witek R.P., et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1093-G1106.
45. Stewart G.A., Hoyne G.F., Ahmad S.A., et al. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol 2003, 199:488-495.
46. Fabian S.L., Penchev R.R., St-Jacques B., et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 2012, 180:1441-1453.
47. Tremblay M.R., Lescarbeau A., Grogan M.J., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009, 52:4400-4418.
48. Ziyadeh F.N., Sharma K. Overview: combating diabetic nephropathy. J Am Soc Nephrol 2003, 14:1355-1357.
49. Zhu Y., Usui H.K., Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol 2007, 27:153-160.
50. Yamamoto T., Nakamura T., Noble N.A., et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814-1818.
51. Sakharova O.V., Taal M.W., Brenner B.M. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 2001, 10:727-738.
52. Kopp J.B., Factor V.M., Mozes M., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003.
53. Ledbetter S., Kurtzberg L., Doyle S., et al. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000, 58:2367-2376.
54. Border W.A., Okuda S., Languino L.R., et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990, 346:371-374.
55. Kasuga H., Ito Y., Sakamoto S., et al. Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis. Kidney Int 2001, 60:1745-1755.
56. Zimmerman B.J., Holt J.W., Paulson J.C., et al. Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules. Am J Physiol 1994, 266:H847-H853.
57. Sato M., Muragaki Y., Saika S., et al. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
58. Inazaki K., Kanamaru Y., Kojima Y., et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004, 66:597-604.
59. Burns W.C., Twigg S.M., Forbes J.M., et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006, 17:2484-2494.
60. Hills C.E., Squires P.E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010, 31:68-74.
61. Bielesz B., Sirin Y., Si H., et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010, 120:4040-4054.
62. Endo T., Okuda T., Nakamura J., et al. Exploring the origin of the cells responsible for regeneration and fibrosis in the kidneys [abstract]. J Am Soc Nephrol 2010, 21:36A.
63. Koesters R., Kaissling B., Lehir M., et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010, 177:632-643.
64. Fraser D., Brunskill N., Ito T., et al. Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-beta 1 synthesis via an autocrine PDGF loop. Am J Pathol 2003, 163:2565-2574.
65. Zhang M., Fraser D., Phillips A. ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. Am J Pathol 2006, 169:1282-1293.
66. Yang L., Besschetnova T.Y., Brooks C.R., et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010, 16:535-543. 1p following 143.
67. Van Geest R.J., Klaassen I., Vogels I.M., et al. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?. Invest Ophthalmol Vis Sci 2010, 51:1857-1865.
68. Strutz F., Zeisberg M., Renziehausen A., et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int 2001, 59:579-592.
69. Strutz F., Zeisberg M., Hemmerlein B., et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 2000, 57:1521-1538.
70. Vasko R., Koziolek M., Ikehata M., et al. Role of basic fibroblast growth factor (FGF-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts. Am J Physiol 2009, 296:F1452-F1463.
71. Floege J., Eitner F., Alpers C.E. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008, 19:12-23.
72. Lassila M., Jandeleit-Dahm K., Seah K.K., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005, 16:363-373.
73. Chen Y.T., Chang F.C., Wu C.F., et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011, 80:1170-1181.
74. Chen Y., Abraham D.J., Shi-Wen X., et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 2004, 15:5635-5646.
75. Abraham S., Kogata N., Fassler R., et al. Integrin beta1 subunit controls mural cell adhesion, spreading, and blood vessel wall stability. Circ Res 2008, 102:562-570.
76. van Nieuwenhoven F.A., Jensen L.J., Flyvbjerg A., et al. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?. Nephrol Dial Transplant 2005, 20:6-10.
77. Nguyen T.Q., Tarnow L., Andersen S., et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29:83-88.
78. Nguyen T.Q., Tarnow L., Jorsal A., et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008, 31:1177-1182.
79. Ponticos M., Holmes A.M., Shi-wen X., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009, 60:2142-2155.
80. Liu S., Shi-wen X., Abraham D.J., et al. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 2011, 63:239-246.
81. Adler S.G., Schwartz S., Williams M.E., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010, 5:1420-1428.